Loading...

Cognition Therapeutics, Inc.

CGTX•NASDAQ
Healthcare
Biotechnology
$0.70
$0.17(31.45%)

Cognition Therapeutics, Inc. (CGTX) Stock Overview

Explore Cognition Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.6/100

Key Financials

Market Cap43.4M
P/E Ratio-1.41
EPS (TTM)$-0.73
ROE-1.94%
Fundamental Analysis

AI Price Forecasts

1 Week$0.25
1 Month$0.11
3 Months$0.00
1 Year Target$0.69

CGTX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Cognition Therapeutics, Inc. (CGTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 80.29, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.69.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.41 and a market capitalization of 43.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

80.29RSI (14)
0.07MACD
33.03ADX
Revenue Growth
0.00%
Profit Growth
$-0.54
↓ 31.73%
EPS Growth
$-0.54
Operating Margin
0.00%
↓ 6.39%
ROE
-194.42%
↓ 31.73%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
3
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$0.00
Average$0.00
High$0.00

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

CEO

Lisa Ricciardi

Employees

25

Headquarters

2500 Westchester Avenue, Purchase, NY

Founded

2021

Frequently Asked Questions

;